MDRX - 4 Healthcare Stocks That Could Test December Highs
CORAL GABLES, FL/ ACCESSWIRE / December 27,2018 / As the new year is rapidly approaching, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. Consumers are more demanding nowadays than previous generations. Companies understand that they not only need to meet the needs and expectations of customers, but design products and services tailored to the specific qualifications of each patient. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Allscripts Healthcare Solutions Inc (NASDAQ: MDRX), ZIOPHARM Oncology Inc (NASDAQ: ZIOP), and Sesen Bio Inc (NASDAQ: SESN) are 4 healthcare stocks worth paying attention to before the end of the year.
Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period. This upswing may be a result of momentum catalyzed by Premier's entering into a binding LOI agreement to acquire all outstanding securities of Cloud Practice Inc last week.
Earlier in the month, Premier Health Group (PHGRF) (PHGI) announced that as part of a strategic growth plan to cover the major verticals associated with primary care, the Company signed another binding Letter of Intent to acquire a Vancouver-based pharmacy. Per the details of the announcement, the acquisition is subject to customary closing conditions, inducing execution of a definitive acquisition agreement and receipt of any required regulatory and stock exchange approvals.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-basedpatient centric model," said Dr. Essam Hamza, CEO of Premier.
For More Information On Premier Health Group, Click Here
Allscripts Healthcare Solutions Inc (MDRX), a global leader in healthcare IT solutions, announced, earlier this month, that it had signed a definitive agreement to sell its interests in Netsmart Technologies Inc. According to the press release, back in 2016, the Company contributed its homecare business to Netsmart, in exchange for a majority ownership stake in the company which has since become the largest tech entity exclusively dedicated to behavioral health and human services.
"Netsmart provides the scale and the depth and breadth of solutions required to navigate the significant opportunities in the post-acute care market, and we are thrilled with how the business has performed over the last two years," said Rick Poulton, Allscripts President. "We believe now is the right time to recognize the significant value we have created by monetizing our investment and improving our balance sheet."
For More Information On Allscripts Healthcare Solutions, Inc, Click Here
ZIOPHARM Oncology Inc (ZIOP) saw its shares enjoy a 1.29% boost to $1.63 per share in midday trading on Thursday. Several weeks ago, the Company announced that it had partnered up with TriArm Therapeutics Ltd to launch Eden Biocell, Ltd, to lead clinical development and commericialtion of Sleeping Beauty-generated CAR-T therapies in the People's Republic of China, Taiwan, and Korea.
Ziopharm CEO Laurence Cooper, M.D., Ph.D., commented on the partnership in an official press release, in which he said: "Advancing our Sleeping Beauty platform in the China region is a key part of both our business development and clinical development strategies," said Dr. Cooper. "James Huang has an outstanding track record of creating value in China, and he and the team at TriArm are ideal partners because they have entrenched relationships with front-line physicians and officials at leading hospitals and regulatory bodies, a commitment to conduct high-quality trials, and state-of-the-art facilities with good manufacturing practices."
For More Information on ZIOPHARM Oncology, Inc, Click Here
Sesen Bio, Inc, (SESN) a late-stage clinical company working on the development of targeted fusion protein therapeutics for cancer treatment, announced on Thursday that its executive leadership team will be hosting a conference call just after the new year to review updated data from its Phase 3 VISTA Trial of Viciniumâ„¢ for the treatment of patients with high-grade non-muscle invasive bladder cancer. In addition to this news, earlier in the month, the Company announced the appointment of Dennis Kim, M.D., as their new chief medical officer.
The company issued a press release welcoming Dr. Kim to the team: "We are thrilled to welcome Dennis to the Sesen Bio team and look forward to leveraging his deep drug development experience, particularly as we approach both six and 12-month data readouts from our VISTA Trial of Vicinium," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. "Dennis has an extensive track record of leading product candidates through development to approval and commercial launch. As the Vicinium program advances, his leadership will be instrumental in helping us bring this novel treatment to patients in need and achieving our mission of saving and renewing the lives of people with cancer."
For More Information On Sesen Bio, Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 — 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com